MedPath

Vitreous Level Of Tumor Necrosis Factor Alpha In Patients With Retinal Vein Occlusion

Completed
Conditions
Retinal Vein Occlusion
Interventions
Diagnostic Test: measurement of vitreous level of tumor necrosis factor alpha
Registration Number
NCT05532475
Lead Sponsor
Kasr El Aini Hospital
Brief Summary

To assess the levels of TNF- α in vitreous samples of patients with retinal vein occlusion prior to administration of intravitreal anti-VEGF and compare them to levels in vitreous samples of normal subjects so as to investigate the association of vitreous tumor necrosis factor with the pathogenesis of retinal vein occlusion.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
40
Inclusion Criteria
  • Any patient with retinal vein occlusion not older than 6 months with no history of Anti-VEGF injection
Exclusion Criteria
  1. Diabetic patients.
  2. Other causes of retinal vascular diseases.
  3. Patients with history of treatment of retinal vein occlusion.
  4. Previous intraocular surgery except cataract surgery performed 6 months before the study.
  5. Subjects with severe systemic inflammatory diseases
  6. Retinal vein occlusion secondary to retinal vasculitis.
  7. All retinal pathologies.
  8. Patients receiving Systemic steroids or Immunosuppressive therapy.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
casesmeasurement of vitreous level of tumor necrosis factor alphapatient with retinal vein occlusion
controlmeasurement of vitreous level of tumor necrosis factor alphacataract patient undergoing cataract surgery
Primary Outcome Measures
NameTimeMethod
to assess vitreous level of tumor necrosis factor alpha in retinal vein occlusion and compare it to patient undergoing cataract surgeryDay 1
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Kasr ALainy University hospital

🇪🇬

Cairo, Egypt

© Copyright 2025. All Rights Reserved by MedPath